HK1165700A1 - Peptides for vaccine against birch allergy - Google Patents

Peptides for vaccine against birch allergy

Info

Publication number
HK1165700A1
HK1165700A1 HK12106173.2A HK12106173A HK1165700A1 HK 1165700 A1 HK1165700 A1 HK 1165700A1 HK 12106173 A HK12106173 A HK 12106173A HK 1165700 A1 HK1165700 A1 HK 1165700A1
Authority
HK
Hong Kong
Prior art keywords
peptides
vaccine against
against birch
birch allergy
allergy
Prior art date
Application number
HK12106173.2A
Other languages
English (en)
Inventor
Roderick Peter Hafner
Paul Laidler
Guy Layton
Mark Larche
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of HK1165700A1 publication Critical patent/HK1165700A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
HK12106173.2A 2010-02-15 2012-06-25 Peptides for vaccine against birch allergy HK1165700A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1002559.1A GB201002559D0 (en) 2010-02-15 2010-02-15 Birch peptides for vaccine

Publications (1)

Publication Number Publication Date
HK1165700A1 true HK1165700A1 (en) 2012-10-12

Family

ID=42110757

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12106173.2A HK1165700A1 (en) 2010-02-15 2012-06-25 Peptides for vaccine against birch allergy

Country Status (21)

Country Link
US (2) US9017689B2 (xx)
EP (2) EP3056213A1 (xx)
JP (2) JP5926198B2 (xx)
KR (1) KR20120120965A (xx)
CN (1) CN102762225B (xx)
AU (1) AU2011214104B2 (xx)
CA (2) CA2789353A1 (xx)
DK (1) DK2536429T3 (xx)
EA (1) EA201290792A1 (xx)
ES (1) ES2573651T3 (xx)
GB (2) GB201002559D0 (xx)
HK (1) HK1165700A1 (xx)
HR (1) HRP20160481T1 (xx)
HU (1) HUE029138T2 (xx)
IL (1) IL221196A0 (xx)
MX (1) MX2012009431A (xx)
NZ (1) NZ602380A (xx)
PL (1) PL2536429T3 (xx)
SG (1) SG183198A1 (xx)
SI (1) SI2536429T1 (xx)
WO (1) WO2011098778A2 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
AU2013216983A1 (en) 2012-02-07 2014-09-18 La Jolla Institute For Allergy And Immunology Epitopes from allergen proteins and methods and uses for immune response modulation
GB201209862D0 (en) 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
GB201211586D0 (en) * 2012-06-29 2012-08-15 Circassia Ltd Japanese cedar peptides for preventing or treating allergy
US20150088644A1 (en) 2013-09-23 2015-03-26 Facebook, Inc., a Delaware corporation Predicting User Interactions With Objects Associated With Advertisements On An Online System
CN106699584B (zh) * 2016-12-30 2018-06-26 南京农业大学 一种利用花粉作为天然催化剂制备的γ-氨基丁酸及其制备方法和应用
NZ759513A (en) 2017-06-01 2022-01-28 Regeneron Pharma Human antibodies to bet v 1 and methods of use thereof
CN110175468B (zh) * 2019-05-05 2020-12-01 浙江工业大学 一种保留分布特征的姓名脱敏方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1994001560A1 (en) 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
US5968526A (en) 1994-04-14 1999-10-19 Immulogic Pharamaceutical Corporation T cell epitopes of the major allergens from Dermatophagoides (house dust mite)
EP1044019A1 (en) 1998-01-09 2000-10-18 Circassia Limited Methods and compositions for desensitisation
FR2788698B1 (fr) 1999-01-27 2001-03-30 Commissariat Energie Atomique Peptides et proteines aptes a desensibiliser les sujets allergiques au venin d'abeille et compositions les contenant
WO2003047618A2 (en) 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
ATE303402T1 (de) 2002-09-27 2005-09-15 Biomay Prod & Handel Hypoallergene impfstoffe gegen allergie basierend auf lieschgraspollenallergen phl p 7
US7923209B2 (en) * 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
WO2008139163A1 (en) 2007-05-09 2008-11-20 Circassia Limited Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
EP2190473B1 (en) * 2007-08-15 2013-01-16 Circassia Limited Peptide with reduced dimer formation
WO2010018384A1 (en) 2008-08-15 2010-02-18 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine

Also Published As

Publication number Publication date
US20130243798A1 (en) 2013-09-19
HUE029138T2 (hu) 2017-02-28
AU2011214104B2 (en) 2015-05-28
AU2011214104A1 (en) 2012-09-06
DK2536429T3 (en) 2016-05-23
WO2011098778A3 (en) 2011-12-15
NZ602380A (en) 2014-10-31
US9017689B2 (en) 2015-04-28
EA201290792A1 (ru) 2013-03-29
HRP20160481T1 (hr) 2016-06-03
CN102762225B (zh) 2015-05-13
CN102762225A (zh) 2012-10-31
JP2013519717A (ja) 2013-05-30
CA3139588A1 (en) 2011-08-18
PL2536429T3 (pl) 2016-09-30
JP5926198B2 (ja) 2016-05-25
KR20120120965A (ko) 2012-11-02
MX2012009431A (es) 2012-09-12
US20150196635A1 (en) 2015-07-16
WO2011098778A2 (en) 2011-08-18
EP3056213A1 (en) 2016-08-17
WO2011098778A8 (en) 2012-09-27
SI2536429T1 (sl) 2016-08-31
GB2481475B (en) 2012-09-19
CA2789353A1 (en) 2011-08-18
GB201102657D0 (en) 2011-03-30
GB201002559D0 (en) 2010-03-31
JP2016166194A (ja) 2016-09-15
IL221196A0 (en) 2012-10-31
GB2481475A (en) 2011-12-28
EP2536429B1 (en) 2016-02-10
ES2573651T3 (es) 2016-06-09
EP2536429A2 (en) 2012-12-26
SG183198A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
IL283139A (en) Proline-locked clamped peptides and their uses
GB201005005D0 (en) New vaccine
IL221196A0 (en) Peptides for vaccine against birch allergy
GB201012651D0 (en) Peptides
EP2605786A4 (en) THERAPEUTIC PEPTIDES
ZA201300395B (en) Influenza vaccine
ZA201307169B (en) Neuroprotective peptides
IL214257A0 (en) Peptides for vaccine
GB201014965D0 (en) Vaccine
EP2627674A4 (en) EGFR BASED PEPTIDES
GB201013006D0 (en) Vaccine
GB201006324D0 (en) Vaccine
ZA201302154B (en) Vaccine
GB201001624D0 (en) Peptides for vaccine
GB201010058D0 (en) Peptide vaccine
GB0902345D0 (en) Peptides for vaccine
GB0917871D0 (en) Peptides for vaccine
GB0902344D0 (en) Peptides for vaccine
GB0901928D0 (en) Peptides for vaccine
GB201010056D0 (en) Polypeptide vaccine
GB201012283D0 (en) Vaccine
GB201007589D0 (en) Vaccine
GB201007588D0 (en) Vaccine
IL228354A0 (en) Neuroprotective peptides
GB201009277D0 (en) Novel vaccine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170215